Complement Component 3 Promotes Leptomeningeal Metastasis [Metastasis]
Cancer cell–derived C3 is essential for the growth of disseminated cancer cells in the CSF. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Metastasis Source Type: research
ENL Is an Essential Acetyl-Histone Reader in Acute Myeloid Leukemia [Leukemia]
ENL binds acetylated histone 3 to promote oncogenic gene expression and AML cell proliferation. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
ETO2-GLIS2 Drives the Transcriptional Program Underlying AMKL [Leukemia]
ETO2–GLIS2 promotes megakaryocytic identify and self-renewal to promote AMKL. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
Combination Immunotherapy Targets Castration-Resistant Prostate Cancer [Immunotherapy]
Targeted therapies that inactivate MDSCs yet spare T-cell function enhance immune checkpoint blockade. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
Inhibition of EZH2 or BET Suppresses Diffuse Intrinsic Pontine Glioma [Epigenetics]
H3K27M-expressing diffuse intrinsic pontine gliomas (DIPG) are dependent on residual PRC2 activity. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Epigenetics Source Type: research
HER2+ Tumor Molecular Subtypes Predict Response to Dual HER2 Blockade [Clinical Trials]
Trastuzumab plus lapatinib achieves the highest response rates in HER2-enriched HER2+ breast tumors. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
ALKBH5 Drives FOXM1 Expression to Promote Brain Tumor Stem Cell Growth [Brain Tumors]
The mRNA demethylase ALKBH5 promotes glioblastoma stem cell growth and tumorigenesis. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Brain Tumors Source Type: research
Immunotherapy Beats Chemo for Bladder Cancer [News in Brief]
Patients with advanced urothelial carcinoma live 3 months longer, on average, when given pembrolizumab as a second-line treatment instead of chemotherapy. The finding is based on data from the first phase III trial to test an immunotherapeutic in these patients, which could lead to another label indication for the PD-1 inhibitor. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
A Different Path for Harnessing TRAIL [News in Brief]
Two studies show that the apoptosis-inducing protein TRAIL also induces release of cytokines that promote tumor growth. TRAIL triggers formation of a signaling complex that activates NF-B. Loss of one component of the signaling complex, the adaptor protein FADD, reduces the number of lung tumors in mice. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
CRISPR Meets CAR T-cell Therapy [News in Brief]
Using CRISPR/Cas9 technology, researchers have devised a method to deliver a CAR gene to a specific locus, TRAC, in T cells. This targeted approach yielded therapeutic cells that were more potent even at low doses; in a mouse model of acute lymphoblastic leukemia, they outperformed CAR T cells created with a randomly integrating retroviral vector. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Budget Cuts Would Harm Research and Patients [News in Brief]
Cancer researchers and administrators have attacked the Trump administration's proposal to cut the NIH budget by nearly 20%. Researchers say that the reduction could hamstring efforts to expand immunotherapies and other novel treatments to more patients. They also worry that the proposal could drive away biomedical scientists and shift top-notch research to other countries. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Monitoring Resistance, Recurrence in NSCLC [News in Brief]
Two studies indicate the importance of serial biopsies in monitoring patients with non–small cell lung cancer. In one, heterogeneous resistance mechanisms to EGFR-targeted therapy were observed, often varying between biopsies for individual patients. In another, circulating tumor cells detected recurrence 6 months earlier, on average, than conventional imaging. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Ribociclib Approved for Advanced Breast Cancer [News in Brief]
The FDA has approved ribociclib combined with aromatase inhibitor therapy for women with metastatic HR-positive, HER2-negative breast cancer. It is the second CDK 4/6 inhibitor approved for these patients, behind palbociclib; a third is under investigation. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Profiling Response, Resistance to Immunotherapy [News in Brief]
In a longitudinal analysis of patients with metastatic melanoma who received sequential therapies targeting CTLA-4, then PD-1 upon disease progression, researchers have discovered that high copy-number loss in recurrent regions of the tumor genome is associated with resistance to immune checkpoint blockade. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Pembrolizumab Approved for Hodgkin Lymphoma [News in Brief]
The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers—and for children. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
